<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669067</url>
  </required_header>
  <id_info>
    <org_study_id>TL-895-203</org_study_id>
    <nct_id>NCT04669067</nct_id>
  </id_info>
  <brief_title>TL-895 and KRT-232 Study in Acute Myeloid Leukemia</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telios Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kartos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Telios Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates TL-895, a potent, orally available and highly selective irreversible&#xD;
      tyrosine kinase inhibitor combined with KRT-232, a novel oral small molecule inhibitor of&#xD;
      MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must&#xD;
      be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective, Phase 1b: To determine the MTD/MAD and recommended Phase 2 dose (RP2D) of TL-895 in combination with KRT-232</measure>
    <time_frame>13 months</time_frame>
    <description>Dose limiting toxicities will be used to established the MTD/MAD of TL-895 combined with KRT-232. The Safety Review Committee (SRC) will determine the RP2D based on safety data of the combination of TL-895 and KRT-232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Objective, Phase 2: To determine the rates of complete remission (CR) and complete remission with partial hematologic recovery (CRh)</measure>
    <time_frame>41 months</time_frame>
    <description>The proportion of subjects who achieved CR or CRh as their best response based on the Modified 2017 European LeukemiaNet (ELN) Response Criteria (Appendix 4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Objective: To characterize the peak plasma concentration (Cmax) of TL-895 and KRT-232</measure>
    <time_frame>13 months</time_frame>
    <description>Cmax of TL-895 and KRT-232</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Objective: To characterize the area under the plasma concentration versus time curve (AUC) of TL-895 and KRT-232</measure>
    <time_frame>13 months</time_frame>
    <description>AUC of TL-895 and KRT-232</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Objective: To characterize the time to Cmax (Tmax) of TL-895 and KRT-232</measure>
    <time_frame>13 months</time_frame>
    <description>Tmax of TL-895 and KRT-232</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Objective: To determine the overall response rate (ORR)</measure>
    <time_frame>41 months</time_frame>
    <description>The proportion of subjects who achieve PR or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Objective: To determine the duration of CR/CRh response (DOR)</measure>
    <time_frame>41 months</time_frame>
    <description>Median DOR (Kaplan-Meier estimate) defined as the time from first observation of CR/CRh to relapse or death from any cause, whichever occurs first. Subjects with MLFS by bone marrow biopsy performed earlier in the course of therapy who convert to CR or CRh do not require a separate bone marrow aspirate at the time of CR or CRh to document this.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>TL-895 combined with KRT-232</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TL-895 will be administered orally, twice a day (BID) continuously starting on Day 1 in a 28-day cycle.&#xD;
KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TL-895</intervention_name>
    <description>TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.</description>
    <arm_group_label>TL-895 combined with KRT-232</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRT-232</intervention_name>
    <description>KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.</description>
    <arm_group_label>TL-895 combined with KRT-232</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  TP53 wildtype AML&#xD;
&#xD;
          -  Relapsed/Refractory to at least one prior therapy, one of which must have included a&#xD;
             FLT-3 inhibitor&#xD;
&#xD;
          -  FLT3 mutation (FLT3-TKD or FLT3-ITD)&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AML subtype 3&#xD;
&#xD;
          -  Prior treatment with MDM2 antagonist therapies&#xD;
&#xD;
          -  Eligible for HSCT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Mei</last_name>
    <phone>650-542-0136</phone>
    <email>jmei@teliospharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evelyn Hang</last_name>
    <phone>650-980-7779</phone>
    <email>ehang@teliospharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center, Division of Hematology Oncology and Cell Therapy</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Sunshine Coast-Sippy Downs</name>
      <address>
        <city>Sippy Downs</city>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Claude Huriez Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Lyon Hospital Center</name>
      <address>
        <city>Lyon</city>
        <zip>48178</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Center Universitaire De Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint-Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Duisburg-Essen, University Hospital Essen, Department of Internal Medicine</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polyclinic S. Orsola-Malpighi, Operative Unit of Hematology</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Romagnolo Scientific Institute of Meldola (IRST) S.r.l., Department of Oncology and Clinical and Experimental Haematology</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital of Valencia, Department of Hematology and Medical Oncology</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico de La Fe</name>
      <address>
        <city>València</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>TP53</keyword>
  <keyword>FLT3+</keyword>
  <keyword>Navtemadlin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

